Canadian clinical practice guidelines for the treating of anxiety, posttraumatic stress and obsessive-compulsive disorders

Navigation article:

Competing interests

Unrestricted educational grants to add mass to the following tips were supplied by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Corporation., Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Corporation., Shire Canada, and Valeant Canada. No people received payment for taking part in the introduction of the following tips.

Authors’ contributions

We thank all co-authors for his or her considerable knowledge of generating the following tips. Authors who have been people from the executive committee (MK, PB, PB, PC, KK, MVA) required part in teleconferences along with a meeting in December 2012 to achieve consensus on the effectiveness of evidence and treatment recommendations. Draft guidelines were then produced by the main committee and revised by all co-authors. The whole content was subsequently circulated to any or all people from the Canadian Anxiety Guidelines Initiative Group for further comments and approval during 2013. GA, LJK, RWL, RSM, and it is provided additional reviews from the comorbidity section. The ultimate manuscript ended up being circulated to exterior reviewers (MP, DS, LDM) and revisions were created according to input in the core committee.